Shawn Misialek
Publications by Year
Research Areas
Hepatitis C virus research, HIV/AIDS drug development and treatment, Quinazolinone synthesis and applications, Hepatitis B Virus Studies, Signaling Pathways in Disease
Most-Cited Works
- → Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)(2008)173 cited
- → Kinetics and Comparative Reactivity of Human Class I and Class IIb Histone Deacetylases(2004)90 cited
- → Characterization and Kinetic Mechanism of Catalytic Domain of Human Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase (VEGFR2 TK), a Key Enzyme in Angiogenesis(1998)74 cited
- → Inhibition and Binding Kinetics of the Hepatitis C Virus NS3 Protease Inhibitor ITMN-191 Reveals Tight Binding and Slow Dissociative Behavior(2009)59 cited
- → Biochemical Role of theCryptococcus neoformansADE2 Protein in Fungalde novoPurine Biosynthesis(1998)27 cited
- → CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo(2006)27 cited
- → HCV NS5B polymerase inhibitors 1: Synthesis and in vitro activity of 2-(1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl)-1-hydroxynaphthalene derivatives(2009)20 cited
- → HCV NS5B polymerase inhibitors 2: Synthesis and in vitro activity of (1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl) azolo[1,5-a]pyridine and azolo[1,5-a]pyrimidine derivatives(2009)15 cited
- → HCV NS5B polymerase inhibitors 3: Synthesis and in vitro activity of 3-(1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl)-4-hydroxy-2H-quinolizin-2-one derivatives(2009)10 cited
- → S134 Kinase Selectivity Profiles Of Nintedanib And Imatinib(2014)7 cited